Catalyst Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel, high-quality medicines for patients living with rare and difficult-to-treat neuromuscular and neurological diseases. The company's commercial portfolio is anchored by three key products: FIRDAPSE (amifampridine), the only FDA-approved treatment for Lambert-Eaton Myasthenic Syndrome (LEMS) in patients aged six and older; AGAMREE (vamorolone), an innovative corticosteroid approved for Duchenne Muscular Dystrophy (DMD) in patients aged two and older; and FYCOMPA (perampanel), an antiepileptic drug for partial-onset and primary generalized tonic-clonic seizures. Catalyst operates on a buy-and-build strategy, acquiring late-stage or commercialized orphan-designated assets to leverage its specialized commercial infrastructure, patient identification, and market access capabilities.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Driving aggressive market penetration strategies for both idiopathic and cancer-associated Lambert-Eaton myasthenic syndrome (LEMS), supported by ongoing patient education and physician outreach.
Expected impact: Expected to drive Firdapse net product revenue to between $435 million and $450 million in 2026, representing 21.4% to 25.6% growth.
Expanding market penetration and commercial adoption of Agamree (vamorolone) for Duchenne Muscular Dystrophy (DMD) in North America, including leveraging partnerships for Canadian commercialization.
Expected impact: Expected to drive Agamree net product revenue to between $140 million and $150 million in 2026, representing 19.6% to 28.1% growth.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Angelini Pharma agreed to acquire Catalyst to establish itself as a relevant global player in neurological rare diseases and secure a commercial foothold in the U.S. market.
Financial impact: Catalyst stockholders will receive $31.50 per share in cash, representing a 21% premium to the unaffected closing price on April 22, 2026.
Strategic Partnerships
Granted Kye exclusive Canadian commercial rights to AGAMREE (vamorolone) for Duchenne Muscular Dystrophy (DMD), expanding the product's footprint in North America.
Terms: Catalyst supplies the product to Kye, which assumes full responsibility for regulatory approval and commercialization in Canada. Santhera obtains royalties from Canadian sales, contributing to sales milestones from Catalyst.